Inadvertent intrathecal administration of vincristine: Time to finally abolish the syringe

@article{Gilbar2019InadvertentIA,
  title={Inadvertent intrathecal administration of vincristine: Time to finally abolish the syringe},
  author={Peter J. Gilbar},
  journal={Journal of Oncology Pharmacy Practice},
  year={2019},
  volume={26},
  pages={263 - 266}
}
  • P. Gilbar
  • Published 10 November 2019
  • Medicine
  • Journal of Oncology Pharmacy Practice
In this edition of the journal, Bruhwiler and Schwappach present results of a survey investigating the implementation of safety measures for vincristine and intrathecal (IT) chemotherapies in Switzerland. Of 21 hospitals who manufactured both parenteral chemotherapy and IT chemotherapy, 16 (76%) still prepared vincristine in syringes mainly in small volumes. The most prevalent safety measures in use were specific labelling for vincristine and special delivery systems for IT medications. They… 

Figures from this paper

Vincristine must NEVER be prepared or administered in a syringe

The authors have stated that, following this incident, an internal procedure for extravasation was updated and vincristine is no longer administered by a syringe but by mini-bag following recommendations by the World Health Organization and the Institute for Safe Medication Practices.

References

SHOWING 1-10 OF 19 REFERENCES

Simple method to eliminate the risk of inadvertent intrathecal vincristine administration.

  • A. StefanouM. Dooley
  • Medicine, Political Science
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
The preparation of vincristine for intravenous bolus administration in a small-volume intravenous bag, as opposed to a syringe, is the only method of completely eradicating the risk of this drug accidentally being given intrathecally.

Inadvertent intrathecal administration of vincristine: Has anything changed?

  • P. Gilbar
  • Medicine
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2012
In 2004, an editorial was published in this journal entitled ‘Inadvertent intrathecal administration of vincristine: are the authors fulfilling their roles as oncology pharmacists?’ and it is again time to ask the question.

Introduction of vincristine mini-bags and an assessment of the subsequent risk of extravasation

  • Z. NurgatM. Smythe M. Aljurf
  • Medicine, Political Science
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2015
The implementation of the international recommendations for vincristine administration in mini-bags to eliminate potential inadvertent intrathecal administration was dependent on stakeholder buy-in and was safe, practical, and feasible in all patient groups.

Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists?

The case of a young man with Burkitt’s lymphoma erroneously administered vincristine intrathecally instead of by the intended intravenous route which resulted in progressive neurotoxicity, paralysis and death is detailed.

Safe vincristine use in Switzerland: Still a long way to go?

  • L. D. BrühwilerD. Schwappach
  • Medicine, Political Science
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2019
Investigating the implementation of safety measures for vincristine and intrathecal chemotherapies in Switzerland found that international recommendations are not widely implemented in Swiss hospitals and patients are still at an increased risk for wrong route application.

The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags

  • P. GilbarC. Carrington
  • Medicine
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2006
The data suggest that vinca alkaloids can be given safely as low volume, short infusions via mini-bags and this practice will prevent the inadvertent intrathecal administration of vinorelbine via syringes.

Medication safety and the administration of intravenous vincristine: International survey of oncology pharmacists

  • P. GilbarC. ChambersM. Larizza
  • Medicine, Political Science
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2015
A number of areas appear to have improved, particularly the preparation of vincristine in mini-bags, but they are far from perfect, and International Society of Oncology Pharmacy Practitioner members are urged to lead the way in incorporating strategies for prevention into institutions worldwide.

Review of case reports of inadvertent intrathecal administration of vincristine: Recommendations to reduce occurrence

Early recognition and immediate treatment with CSF drainage and intrathecal exchange appears to be the only intervention that has improved patient survival and volume of injection, dose and time from the incident until the ventriculo‐lumbar washout appear critical.

Fatality resulting from intraventricular vincristine administration.

Despite aggressive and immediate therapy, intraventricular vincristine infusion produced neurologic toxicity, with progressive loss of mental function, followed by coma and death, and systems need to be developed to prevent inadvertent central nervous system administrations.

The death of an infant after the unfortunate intrathecal injection of vincristine

The results indicate that the aminoglycoside-resistance genes are highly prevalent and could easily spread among P. aeruginosa strains, and Coordinated efforts and further research works are needed to control antibiotic resistance to am inoglycosides before to be a threatening crisis.